Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
June 9, 2026
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
May 26, 2026
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
May 25, 2026
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors
May 23, 2026
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
May 22, 2026
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M
January 23, 2026
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
January 22, 2026
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
January 21, 2026
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 20, 2026